# Quantitative Structure-Activity Relationship Models with Receptor-Dependent Descriptors for Predicting Peroxisome Proliferator-Activated Receptor Activities of Thiazolidinedione and Oxazolidinedione Derivatives 

Viney Lather, Visvaldas Kairys and Miguel X. Fernandes*<br>Centro de Química da Madeira, Departamento de Química, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal<br>*Corresponding author: Miguel X. Fernandes, mxf@uma.pt


#### Abstract

A quantitative structure-activity relationship study has been carried out, in which the relationship between the peroxisome proliferator-activated receptor $\alpha$ and the peroxisome proliferatoractivated receptor $\gamma$ agonistic activities of thiazolidinedione and oxazolidinedione derivatives and quantitative descriptors, $V_{\text {site }}$ calculated in a receptor-dependent manner is modeled. These descriptors quantify the volume occupied by the optimized ligands in regions that are either common or specific to the superimposed binding sites of the targets under consideration. The quantitative structure-activity relationship models were built by forward stepwise linear regression modeling for a training set of 27 compounds and validated for a test set of seven compounds, resulting in a squared correlation coefficient value of 0.90 for peroxisome proliferator-activated receptor $\alpha$ and of 0.89 for peroxisome proliferator-activated receptor $\gamma$. The leave-one-out cross-validation and test set predictability squared correlation coefficient values for these models were 0.85 and 0.62 for peroxisome proliferator-activated receptor $\alpha$ and 0.89 and 0.50 for peroxisome proliferator-activated receptor $\gamma$ respectively. A dual peroxisome proliferator-activated receptor model has also been developed, and it indicates the structural features required for the design of ligands with dual peroxisome proliferator-activated receptor activity. These quantitative structure-activity relationship models show the importance of the descriptors here introduced in the prediction and interpretation of the compounds affinity and selectivity.


Key words: multiple linear regression, peroxisome proliferator-activated receptor, quantitative structure-activity relationship

Received 12 August 2008, revised 15 January 2009 and accepted for publication 21 January 2009

The study of relationships between molecular structure and properties, either physicochemical or biological, has attracted considerable attention and forms the basis of quantitative structure property/activity relationship (OSPR/OSAR) studies. During the past decades, thousands of molecular descriptors such as graph-theoretic, geometric, electrostatic, quantum-chemical, etc. have been extensively used for the prediction of physical, chemical, environmental and biological properties of molecules (1). Computation of these molecular descriptors for QSAR studies is generally carried out in a receptor-independent manner except in some cases, where the alignment of molecules is based either on a co-crystallized ligand or on the docked conformations for CoMFA and CoMSIA studies $(2,3)$. A receptor-dependent QSAR approach has been incorporated in 4D-QSAR and 5D-QSAR approaches, and 4D-OSAR analysis has been used in the design of inhibitors of glycogen phosphorylase (4) and HIV-1 protease inhibitors (5). With the available panoply of descriptors, several OSAR equations could describe equally well the experimental data under study. Nonetheless, from a medicinal chemist's standpoint QSAR models should be easily interpreted and their predictions easily translated into synthesis of new compounds with improved properties. In this sense, descriptors and QSAR models with simple and intuitive interpretation are at premium.

An increasing realization in drug discovery is that modulating a multiplicity of targets can be an asset in the treatment of a range of disorders. Examples include: Omapatrilat, a dual angiotensinconverting enzyme and neutral endopeptidase inhibitor (6); SKI-606, a dual inhibitor of Src and Abl kinases (7); Netoglitazone, a peroxisome proliferator-activated receptor; PPAR $\alpha$ and PPAR $\gamma$ agonist (8). In this study, we introduce novel molecular descriptors which incorporate receptor information, and are conceived to be used in cases where ligands are being designed to target several receptors. These quantitative descriptors, $V_{\text {site }}$, measure the volume occupied by a ligand within the common or specific regions defined by the superimposed binding sites of the targets under consideration, as receptors targeted by the same ligand should share some common features in their binding sites. Therefore, ligands that are active against several receptors should preferentially remain, and interact,
within the region that is common to the binding sites of all targeted receptors. We want to test if the selectivity of ligands for multiple receptors is correlated with the volume, they occupy within the common region defined by the binding sites. The descriptors that we are introducing are very simple and take into account only the steric nature of the binding sites to define common or specific regions, and sometimes other factors (chemical nature, flexibility of ligands, conformational changes of receptors, etc.) could play a more important role than these simple descriptors, we are introducing. The proposed descriptors were used along with other molecular descriptors, in the development of 2D-OSAR models for the prediction of PPAR $\alpha$, PPAR $\gamma$ and PPAR $\alpha / \gamma$ dual agonistic activity of a dataset of thiazolidinedione and oxazolidinedione derivatives from the lead compound KRP-297 of Merck which showed PPAR $\alpha / \gamma$ dual activity. This set of compounds was studied by Khanna et al. and the authors established a 3D-QSAR model based on the additivity of molecular fields, but the study was carried out in a receptorindependent manner (9).

## Materials and Methods

## Dataset for analysis

A dataset consisting of a series of 5-aryl thiazolidinedione and oxazolidinedione derivatives $(10,11)$ acting as PPAR $\alpha$ and PPAR $\gamma$ dual activators has been selected to develop three OSAR models: (i) $\alpha$ model, (ii) $\gamma$ model and (iii) dual model. The basic structures of these compounds are shown in Table 1 along with their induced activities for PPAR $\alpha$ and PPAR $\gamma$ ( $\mathrm{plC}_{50}$ ). In the dual model development, $\mathrm{plC}_{50}$ (dual) have been calculated as the summation of $\mathrm{plC}_{50}$ values for PPAR $\alpha$ and PPAR $\gamma$. The dataset of 34 molecules was subdivided randomly into a training set and a test set of 27 and seven molecules, respectively (as selected by Khanna et al. for the CoMFA studies). Two molecules which were excluded from Khanna's study because of not-fitting into the model were included in this study as part of the test set molecules. Khanna's report includes compounds for which $\mathrm{IC}_{50}$ values of PPAR $\alpha$ activity could not be specifically ascertained, but a minimum range was defined. For such molecules, the reported minimum value of activity was employed in the development of QSAR models.

## Computational details

## Active/inactive classification

The new descriptors here introduced (see below) will have a zero value for those compounds that are inactive towards a certain target. We are assuming that inactive compounds will not remain in the target's binding site and therefore they do not occupy any volume in that binding site. This does not pose any problem for compounds with known activities, where we calculate the descriptors only for the active compounds. However, in a context of quantitative prediction of activities of unknown compounds, we will need an a priori qualitative classification of these compounds, either as active or inactive, before the calculation of the descriptors. To determine if an unknown compound will be considered as active or inactive for a particular receptor isoform, and therefore if the descriptors here introduced need to be calculated or not, a
qualitative approach for classifying the molecules from the dataset has been implemented. The relationship of the Zagreb index - an adjacency based topological descriptor $(12,13)$ and the Balaban-type index from polarizability weighted distance matrix, $J_{p}$ - a distancebased topological descriptor $(14,15)$ with the PPAR $\alpha$ and the PPAR $\gamma$ agonistic activities was investigated by the development of suitable models. The Zagreb index $M_{1}$ proposed by Gutman et al. $(12,13)$ is defined as the sum of squares of degree over all vertices and is represented by the following equation:

$$
\begin{equation*}
M_{1}=\sum_{i=1}^{n}\left(V_{i}^{2}\right) \tag{1}
\end{equation*}
$$

where $V_{i}$ is the degree of vertex $i$ in a hydrogen-suppressed molecular structure. The vertex degree $V_{i}$ for a vertex $i$ is given as the sum of the entries in a row $i$ of the adjacency matrix.

The Balaban index $(\mathcal{J})$ proposed by Balaban (14) is calculated using the following formula:

$$
\begin{equation*}
J=\frac{B}{C+1} \sum_{k=1}^{B} \sqrt{\left(v_{i} v_{j}\right)_{k}} \tag{2}
\end{equation*}
$$

where $v_{i}$ and $v_{j}$ are the vertex distance degrees of two atoms connected by bond $k, B$ is the number of bonds of the molecule and $C$ is the cyclomatic number. The Balaban-type index, $J_{p}$ is obtained by weighting the contributions of atoms and bonds with polarizability (15). The topological indices $M_{1}$ and $J_{p}$ were calculated using E-Dragon (VCCLAB, Virtual Computational Chemistry Laboratory, 2005).

Values of the Zagreb index were computed for each compound. For the selection and evaluation of range-specific features, exclusive activity ranges were discovered from the frequency distribution of response level, and subsequently identifying the active range by analyzing the resultant data by maximization of the moving average with respect to the active compounds (16). Subsequently, each compound in the dataset was classified using this model, and its classification was compared with the experimental values of PPAR $\alpha$ and PPAR $\gamma$ activities ( $\mathrm{IC}_{50}$ ). Compounds possessing $\mathrm{IC}_{50}$ values $\leq 2 \mu \mathrm{M}$ were considered as active and analogs possessing $\mathrm{I}_{50}$ values $>2 \mu \mathrm{M}$ were considered as inactive in this study. The percentage of successful prediction of active and inactive range was calculated from the ratio of the number of compounds predicted correctly to the total number of compounds present in that range. The overall percentage of successful prediction was calculated from the ratio of the total number of compounds predicted correctly to that of the total number of compounds present in both the active and inactive ranges. The aforementioned procedure was similarly adopted for the Balaban type index. As no compound in the dataset possessed PPAR $\gamma \mathrm{I}_{50}$ value $>2 \mu \mathrm{~m}$, all the compounds were considered as active and the calculation of volumes within the PPAR $\gamma$ binding site was performed.

## Optimization of ligands and calculation of $\boldsymbol{V}_{\text {site }}$

The molecular structures of the compounds were built with HYPERснем (Hypercube Inc, Gainsville, FL, USA) using the crystal structure

## Lather et al.

Table 1: Dataset used for OSAR analysis with their plC $C_{50}$ values in the $\alpha, \gamma$ and dual models


| Comp. <br> No. | X | R | $M_{1}$ | $J_{p}$ | Exp. PPAR $\alpha$ activity | Pred. <br> PPAR <br> activiv <br> $M_{1}$ | $J_{p}$ | $\begin{aligned} & \text { Exp. } \\ & p \mid C_{50} \\ & (\alpha) \end{aligned}$ | Pred. $\mathrm{plC}_{50}$ <br> (a) | $\begin{aligned} & \text { Exp. } \\ & \text { pIC }_{50} \\ & (\gamma) \end{aligned}$ | Pred. $\mathrm{plC}_{50}(\gamma)$ | Exp. $\mathrm{plC}_{50}$ (dual) | Pred. <br> plC50 <br> (dual) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | S |  | 172 | 0.861 | + | + | + | 7.55 | 7.25 | 7.24 | 7.29 | 14.80 | 14.20 |

$\mathbf{2}^{\mathrm{a}, \mathrm{b}} \quad \mathrm{S}$

$3^{\mathrm{c}} \quad \mathrm{S}$



| 196 | 0.877 | - | - | - | 5.68 | 5.11 | 6.77 | 6.80 | 12.45 | 12.22 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |



192 0.870 - $\quad$ - 5.0
5.09
6. 6.47

4 S



0763
-
$202-0.763$

-     - 5.0
5.22
. 22
6.54

664

$206 \quad 0.774$
-

- $\quad$ - 5.70
5.40 6.48

6. 

Table 1: (Continued)

| Comp. No. | X | R | $M_{1}$ | $J_{p}$ | Exp. <br> PPAR $\alpha$ <br> activity | Pred <br> PPA <br> activ <br> $M_{1}$ | $J_{p}$ | Exp. $\mathrm{plC}_{50}$ $(\alpha)$ | Pred. $\mathrm{plC}_{50}$ ( $\alpha$ ) | Exp. <br> $\mathrm{plC}_{50}$ <br> $(\gamma)$ | Pred. $\mathrm{plC}_{50}(\gamma)$ | Exp. <br> $\mathrm{plC}_{50}$ <br> (dual) | Pred. <br> $\mathrm{plC}_{50}$ <br> (dual) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $13^{\text {a }}$ | S |  | 218 | 0.788 | + | + | + | 7.17 | 7.09 | 7.19 | 6.94 | 14.36 | 15.54 |
| 14 | S |  | 218 | 0.782 | + | + | + | 6.79 | 6.78 | 7.25 | 6.94 | 14.04 | 14.46 |
| 15 | S |  | 172 | 0.849 | + | + | + | 6.95 | 6.73 | 7.11 | 7.00 | 14.06 | 13.80 |
| 16 | S |  | 176 | 0.852 | + | + | + | 5.85 | 6.66 | 7.43 | 7.21 | 13.28 | 13.86 |
| 17 | S |  | 168 | 0.850 | + | + | + | 6.68 | 6.50 | 7.07 | 7.02 | 13.75 | 12.98 |
| 18 | S |  | 178 | 0.949 | + | + | + | 7.38 | 7.16 | 7.20 | 7.28 | 14.58 | 14.45 |
| 19 | S |  | 184 | 0.961 | + | + | + | 7.05 | 7.30 | 7.72 | 7.72 | 14.77 | 13.92 |
| $20^{\text {a }}$ | S |  | 190 | 0.850 | - | - | + | 5.0 | 6.20 | 6.84 | 6.91 | 11.84 | 14.23 |
| 21 | S |  | 178 | 0.935 | + | + | + | 7.43 | 7.30 | 7.52 | 7.50 | 14.95 | 14.89 |
| 22 | S |  | 172 | 0.927 | + | + | + | 6.92 | 6.80 | 7.19 | 7.00 | 14.11 | 13.85 |
| 23 | S |  | 172 | 0.913 | + | + | + | 7.21 | 7.29 | 6.82 | 6.75 | 14.03 | 14.52 |
| 24 | S |  | 168 | 0.917 | + | + | + | 7.34 | 7.14 | 7.23 | 7.17 | 14.57 | 14.73 |
| $25^{\text {a }}$ | S |  | 168 | 0.882 | - | + | - | 5.30 | 5.87 | 6.47 | 7.16 | 11.77 | N.A. |
| 26 | 0 |  | 168 | 0.896 | + | + | + | 6.54 | 6.70 | 6.31 | 6.23 | 12.85 | 12.55 |

## Lather et al.

Table 1: (Continued)

| Comp. <br> No. | X | R | $M_{1}$ | $J_{p}$ | Exp. <br> PPAR $\alpha$ <br> activity | Pred <br> PPAR <br> activ <br> $M_{1}$ | $J_{p}$ | Exp. <br> $\mathrm{plC}_{50}$ <br> $(\alpha)$ | Pred. <br> $\mathrm{plC}_{50}$ <br> ( $\alpha$ ) | Exp. <br> $\mathrm{plC}_{50}$ <br> $(\gamma)$ | Pred. <br> $\mathrm{plC}_{50}(\gamma)$ | Exp. <br> $\mathrm{plC}_{50}$ <br> (dual) | Pred. <br> $\mathrm{plC}_{50}$ <br> (dual) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 27 | 0 |  | 172 | 0.893 | - | + | + | 5.58 | 5.65 | 6.35 | 6.26 | 11.92 | 12.34 |
| 28 | 0 |  | 164 | 0.873 | + | + | - | 6.21 | 6.58 | 6.19 | 6.13 | 12.40 | 11.93 |
| $29^{\text {a }}$ | 0 |  | 174 | 0.890 | + | + | + | 6.20 | 7.04 | 5.97 | 6.36 | 12.17 | 13.30 |
| 30 | 0 |  | 174 | 0.886 | - | + | - | 4.82 | 5.24 | 5.94 | 6.20 | 10.76 | 11.33 |
| 31 | 0 |  | 182 | 0.886 | - | + | - | 4.82 | 4.46 | 6.74 | 6.52 | 11.56 | 11.88 |
| 32 | 0 |  | 182 | 0.901 | + | + | + | 6.23 | 6.23 | 6.27 | 6.07 | 12.50 | 12.68 |
| 33 | 0 |  | 168 | 0.876 | - | + | - | 5.48 | 5.34 | 5.75 | 6.02 | 11.23 | 11.71 |
| 34 | 0 |  | 176 | 0.848 | - | + | + | 5.54 | 5.30 | 6.12 | 6.25 | 11.66 | 11.34 |

${ }^{\text {a }}$ Test set molecules; ${ }^{\text {b }}$ without propyl group; ${ }^{\mathrm{c}} n=2$.
of rosiglitazone with PPAR $\gamma$ [PDB:2PRG (17)] as the basic skeleton. All compounds were then optimized individually using semi-empirical quantum mechanics (PM3 method with restricted Hartree-Fock) to get the correct bond lengths and angles. The compounds with correct geometries were docked against the PPAR isoforms using VDock (18). If for a given receptor, a particular compound was classified as inactive, then that compound would not be docked against the receptor.

The volumes of the compounds within a $4 \AA$ threshold from receptor atoms were calculated using a simple in-house gridbased algorithm programmed in FORTRAN ${ }^{\text {a }}$. The receptor atom co-ordinates were read from a specially prepared PDB file containing the two superimposed PPAR variants (PPAR $\gamma ;$ PDB:2PRG and PPAR $\alpha ;$ PDB:117G). The structural alignment of the two proteins was carried out based upon the co-ordinates of the protein's $\mathrm{C} \alpha$ atoms using the SHEBA program (19). For each docked ligand, a relatively small virtual 3 D grid with a $0.2 \AA$ spacing was created, completely enveloping the entire van der Waals volume of the ligand molecule. The grid points that fall outside of the ligand
atom's van der Waals radii were ignored. For each grid point inside the ligand's van der Waals radii, the test of the proximity to the receptor atoms was performed. The program classified each grid point as belonging to one of the following categories: (i) within $4 \AA$ from both PPAR $\alpha$ and $\gamma$ receptors; (ii) within $4 \AA$ from PPAR $\alpha$ but outside of the $4 \AA$ zone of PPAR $\gamma$ (PPAR $\alpha$ only); (iii) within $4 \AA$ from PPAR $\gamma$ but outside of the $4 \AA$ zone of PPAR $\alpha$ (PPAR $\gamma$ only); and (iv) outside of the $4 \AA$ zone of both PPAR $\alpha$ and $\operatorname{PPAR} \gamma$ receptors. Figure 1 illustrates schematically the calculated volumes used in this study. The numbers of grid points falling within each category were further multiplied by the volume of a grid cell, i.e. $0.008 \AA^{3}$, and produced the numerical values of $V_{\text {common, }} V_{\alpha,} V_{\gamma}$ and $V_{\text {out, }}$ corresponding to the four categories mentioned above. Only the heavy (non-hydrogen) atoms of the ligand and of the receptor were taken into account by the program. In cases where compounds presented dual activity, $V_{\alpha}$ and $V_{\gamma}$ were calculated using the compounds' docked conformation in PPAR $\alpha$ and PPAR $\gamma$, respectively. $V_{\text {common }}$ and $V_{\text {out }}$ of a dual active compound were calculated as averages for both conformations of the compound docked separately against the PPAR $\alpha$ - and the


Figure 1: Schematic illustration of volumes used in this paper. The relevant volumes are computed by superposing two PPAR isoforms (thin sticks), creating van der Waals spheres around the ligand atoms (the upper half of the picture), and calculating volumes of the ligand within the $r=4 \AA$ threshold from the protein atoms of either isoform. The volumes obtained can be classified into four categories: part of the ligand far from atoms belonging to either PPAR $\alpha$ or PPAR $\gamma$ isoforms (uncolored field), close to PPAR $\alpha$ but far from PPAR $\gamma$ (light blue), close to PPAR $\gamma$ only (dark blue) and close to both PPAR $\alpha$ and PPAR $\gamma$ (stripes).

PPAR $\gamma$ binding sites. If a compound was considered inactive towards PPAR $\alpha$, then it was not docked in the receptor's binding site and its $V_{\alpha}$ value was set to zero. For a compound inactive towards PPAR $\alpha, V_{\text {common }}$ and $V_{\text {out }}$ were calculated using only the compound's docked conformation against the PPAR $\alpha$ binding site, and the same happened obviously for the calculation of $V_{\gamma}$ The values of $V_{\alpha \prime} V_{\gamma,} V_{\text {common, }}, V_{\text {out }}$ and the molecular volume for some compounds used in this study are shown in Table 2.

## Choice of descriptors

The molecular structures were extracted from the proteins after docking and transferred to a database for the calculation of other molecular descriptors including constitutional, topological, geometrical, electrostatic and quantum descriptors using CODESSA ${ }^{\text {TM }}$ (Comprehensive Descriptors for Structural and Statistical Analysis) program ${ }^{\text {b }}$ (20). A total of 527 descriptors were calculated for all the structures. Selection of descriptors was performed in a heuristic manner as employed in the framework of CODESSA which reduces the pool of descriptors by eliminating those that satisfy the following conditions (21): (i) descriptors that were not available for every structure; (ii) the descriptor has a constant value for all the investigated compounds; (iii) the descriptors with a correlation coefficient smaller than 0.3 with the dependent variable ( $\mathrm{plC}_{50}$ ) were regarded as redundant; (iv) in the monoparametric correlation with ( $\mathrm{plC}_{50}$ ), the descriptor has a squared correlation coefficient lower than 0.1 ; (v) in the monoparametric correlation the descriptor has a $t$-test value lower than 0.1 ; (vi) in the monoparametric correlation the descriptor has an $F$-test value lower than 1 at a probability level of 0.05 ; (vii) highly correlated descriptors provide

Table 2: Numerical values of $V_{\alpha}, V_{\gamma,}, V_{\text {common }}, V_{\text {out }}$ and molecular volume of representative thiazolidinedione and oxazolidinedione derivatives

| Comp. No. | $V_{\alpha}$ | $V_{\gamma}$ | $V_{\text {common }}$ | $V_{\text {out }}$ | Molecular <br> volume |
| :--- | :---: | :--- | :--- | :--- | :--- |
| $\mathbf{1}$ | 17.94 | 5.86 | 333.36 | 1.40 | 368.30 |
| $\mathbf{4}$ | 0 | 5.66 | 361.54 | 2.73 | 411.30 |
| $\mathbf{1 0}$ | 18.71 | 5.87 | 342.62 | 1.33 | 372.30 |
| $\mathbf{1 3}$ | 18.52 | 6.03 | 363.54 | 1.38 | 399.70 |
| $\mathbf{1 5}$ | 27.70 | 5.87 | 339.72 | 3.65 | 386.60 |
| $\mathbf{1 8}$ | 23.43 | 6.46 | 332.90 | 1.34 | 371.50 |
| $\mathbf{2 3}$ | 22.40 | 5.66 | 344.72 | 1.29 | 387.10 |
| $\mathbf{2 5}$ | 0 | 7.35 | 330.90 | 1.46 | 378.50 |
| $\mathbf{2 8}$ | 20.57 | 6.95 | 331.80 | 1.56 | 381.40 |
| $\mathbf{3 2}$ | 21.42 | 7.34 | 335.85 | 1.54 | 375.10 |

approximately identical information, if their pair-wise correlation coefficient exceeded 0.75 .

## OSAR models generation

A heuristic approach was used for the initial selection of molecular descriptors followed by forward feature selection with multiple linear regressions (MLRs) to establish the final OSAR models. The final OSAR models were built using statistica 7.0 (Statsoft Inc, Tulsa, OK, USA). Using the Fisher test ( $F$-value) for the analysis of variance, squared correlation coefficient $\left(R^{2}\right)$ and standard error of estimate (SEE), of training set as criteria of selection, subsets of descriptors were examined for establishing the best linear QSAR. The size of the descriptors subset used for model establishment was increased until no improvement was seen as well as keeping in view that the number of compounds in the training set should not be smaller than five times the number of descriptors. Variance-covariance matrices were calculated for each of the descriptors in all of the resulting linear models and the descriptors which had multicollinearity, were discarded. Tolerance and variation inflation factor (VIF) were chosen as the parameters for determining the collinearity among the variables. VIF values between 1 and 10 are acceptable for indicating the non-collinearity. Among the remaining models after the elimination process, the one that had the minimum RMSE was chosen as the best. The goodness of the regression fits were estimated using parameters, such as $R^{2}$, RMSE and $F$-statistics. To assess the self-consistency, the final model was validated using leave-one-out (LOO) and the predictive ability was checked using cross-validated squared correlation coefficient $\left(q^{2}\right)$. After model development with a randomly selected set of training compounds, the best model was further examined by the test set molecules.

## Results and Discussion

## Active/inactive classification

The relationship of the Zagreb index and the Balaban-type index with the PPAR $\alpha$ activity of compounds in the dataset was investigated and suitable models were developed to provide the behavior (active or inactive) of an unknown compound (not included in the dataset), through exploitation of the active ranges drawn from the

## Lather et al.

proposed models. Retrofit analysis of the data in Tables 3 and 4 reveals the following information concerning the different models developed in this study.

Classification based upon the Zagreb index.

- A total of 27 of 34 compounds were classified correctly in both the active and inactive ranges. The overall accuracy of prediction was found to be $80 \%$ with respect to PPAR $\alpha$ agonistic activity.
- The inactive range traversed between the two active ranges and had a $M_{1}$ value of 188-212. Eight of nine analogs in the inactive range were predicted correctly resulting in a prediction of $89 \%$. The average $\mathrm{IC}_{50}$ value for the inactive range was found to be $5.75 \mu \mathrm{~m}$, indicating the presence of highly inactive compounds.
- The lower active range had a $M_{1}$ value of $<188$ and the upper active range had a $M_{1}$ value of $>212$. The lower active range had a predictability percentage of $72 \%$, while the upper range resulted in $100 \%$ predictability. The average $\mathrm{IC}_{50}$ value for the upper active range was found to be $0.30 \mu \mathrm{~m}$, indicating the presence of highly active compounds.


## Classification based upon the Balaban-type index:

- A total of 28 of 34 compounds were classified correctly in both the active and inactive ranges. The overall accuracy of prediction was found to be $82.4 \%$ with respect to PPAR $\alpha$ agonistic activity.
- Two active ranges, i.e. lower and upper active range were identified. The lower active traversed between the two inactive ranges and had a $J_{p}$ value of $0.782-0.861$. Eight of 10 analogs were predicted correctly resulting in a prediction of $80 \%$. The average $\mathrm{IC}_{50}$ value for the lower active range was found to be $1.58 \mu \mathrm{~m}$, indicating the presence of more active compounds.
- The upper active range had $J_{p}$ values of $>0.886-0.961$. Nine of 10 analogs in the active range exhibited the PPAR $\alpha$ agonistic activity. The average $\mathrm{I}_{50}$ value for the upper active range was found to be $0.45 \mu \mathrm{~m}$, indicating the presence of highly active compounds.
- The inactive ranges had $J_{p}$ values of $<0.782$ and $>0.861-0.886$. The average $\mathrm{IC}_{50}$ values of the inactive ranges were found to be 4.11 and $7.00 \mu \mathrm{~m}$, respectively, indicating the presence of highly inactive compounds compared with active ranges.

The developed classification models revealed significant correlations between the topological indices and PPAR $\alpha$ agonistic activity of thiazolidinedione and oxazolidinedione derivatives. The model based upon the Balaban-type index; a distance-based topological descriptor resulted in a better model as compared with the model based on Zagreb index; an adjacency based topological descriptor. Thus, these models could be used to predict the behavior (active/inactive) of unknown compounds whose numerical activity will be predicted using the OSAR equations presented below.

## QSAR models

Three independent QSAR models were developed using the volumes occupied by the ligands in the receptors' binding sites and other molecular descriptors calculated by CODESSA. The generated models include: (i) the PPAR $\alpha$ model, developed using the ligands' induced activity of PPAR $\alpha$ as the dependent variable, (ii) the PPAR $\gamma$ model, using the ligands' induced activity of $\operatorname{PPAR} \gamma$ as the dependent variable, (iii) the PPAR dual model, using the multiplication of the activities induced by the ligands for both receptors. A linear regression with forward feature selection approach was carried out for the development of all three models. The volumes calculated for the molecules docked against the PPAR $\alpha$ and the PPAR $\gamma$ binding sites were used in the OSAR models for the prediction of PPAR $\alpha$ and $\operatorname{PPAR} \gamma$ agonistic activities, respectively. As mentioned earlier, the

| Model <br> index | Nature of range in the proposed model | Index value | No. compounds falling in the range |  | Percent accuracy | Average$\mathrm{IC}_{50}(\mu \mathrm{M})$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Total | Correct |  |  |
| $M_{1}$ | Lower active | <188 | 21 | 15 | 72 | 2.29 |
|  | Inactive | 188-212 | 09 | 08 | 89 | 5.75 |
|  | Upper active | >212 | 04 | 04 | 100 | 0.30 |


| Model index | Nature of range in the proposed model | Index value | Nature of compounds falling in the range |  | Percent accuracy | Average $\mathrm{IC}_{50}(\mu \mathrm{~m})$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Total | Correct |  |  |
| $J_{p}$ | Inactive | $<0.782$ | 06 | 04 | 67 | 4.11 |
|  | Lower active | 0.782-0.861 | 10 | 08 | 80 | 1.58 |
|  | Inactive | $>0.861-0.886$ | 08 | 07 | 87 | 7.00 |
|  | Upper active | $>0.886-0.961$ | 10 | 09 | 90 | 0.45 |

Table 3: Proposed model for PPAR $\alpha$ activity based on Zagreb index
volumes, $V_{\alpha,}$ for molecules which were inactive for PPAR $\alpha$ were set to zero.

## PPAR $\alpha$ model

The initial pool of descriptors calculated by CODESSA was reduced to a minimum of 21 in heuristic manner followed by a stepwise MLR model generation using forward feature selection. The best MLR model resulted in a 5 -parameter equation:
$p \mathrm{Cl} \mathrm{C}_{50}(\alpha)=0.054( \pm 0.006) V_{\alpha}-0.707( \pm 0.0165)$ Topograhic electronic index (all pairs) $+3.433( \pm 1.160) \mathrm{XY}$ shadow $-0.348( \pm 0.127)$ HA-dependent HDCA-1 $-6.805( \pm 3.096) \quad Z X \quad$ shadow +12.899 $( \pm 2.042)$
$n=27, R^{2}=0.903, F(5,21)=39.007$, SEE $=0.322, q^{2}=0.849$
The pentavariant model explained $90 \%$ of the variance in activity. The statistical details are shown in Table 5. All the $t$-values are significant with low $p$-values which confirm the significance of each descriptor. The $F$-statistics (on 5 and 21 degrees of freedom) for this model was found to be 39.0 with a p-value lower than 0.000 . Further, the variance inflation factors are smaller than 1.6 , which indicates the absence of multicollinearities in the model. Thus, the model is considered to be statistically valid. The predictive ability of the model was validated internally by LOO method resulting in a $q^{2}$ value of 0.85 , which eliminates the possibility of chance correlation in the model and also indicates that the model is highly predictive. The RMSE for the training set $\left(R^{2}=0.90\right)$ was 0.28 and the RMSE for the prediction/test set ( $R^{2}=0.62$ ) was 0.60 . Figure 2 shows a fit plot of predicted versus experimental $\mathrm{plC}_{50}$ values for the training and test set molecules.

The main descriptor for the prediction of the PPAR $\alpha$ agonistic activity as deduced from the $t$-statistics was found to be the $V_{\alpha,}$ which is the volume occupied by the ligands in the region specific of PPAR $\alpha$ 's binding site. A positive coefficient value indicates that an increase in the volume or size of ligands in this PPAR $\alpha$-specific binding region increases the biological activity. Probably, this happens because an increase in the bulk leads to increased hydrophobic interactions (the region of the binding site accounting for $V_{\alpha}$ is lined with hydrophobic residues) thus enhancing biological activity.

The second descriptor of importance is the topographic electronic index (all pairs), which is derived from Zefirov's partial charges (22).

Table 5: Statistics for the best MLR model for prediction of PPAR $\alpha$ agonistic activity

| Descriptor | beta | SE | $t$ | p level | Tolerance | VIF |
| :--- | ---: | :--- | :--- | :--- | :--- | :--- |
| Constant | 12.899 | 2.042 | 6.315 | 0.000 |  |  |
| $V_{\alpha}$ | 0.054 | 0.006 | 8.835 | 0.000 | 0.840 | 1.190 |
| Topographic | -0.707 | 0.165 | -4.263 | 0.000 | 0.845 | 1.183 |
| electronic index |  |  |  |  |  |  |
| XY shadow | 3.433 | 1.160 | 2.958 | 0.007 | 0.886 | 1.128 |
| HA dependent | -0.348 | 0.127 | -2.740 | 0.010 | 0.836 | 1.196 |
| HDCA-1 | -6.805 | 3.096 | -2.198 | 0.010 | 0.838 | 1.193 |
| $Z X$ shadow |  |  |  |  |  |  |



Figure 2: Plots of predicted versus experimental PPAR $\alpha$ activities of the training and test set molecules.

This descriptor reflects the electrostatic interactions between the ligands and receptor molecules, and can characterize the charge distribution in the ligands. Negative contribution of this descriptor indicates the importance of other forces like hydrophobic interactions between ligands and PPAR $\alpha$.

The third descriptor is the $X Y$ shadow/ $X Y$ rectangle which is a geometrical descriptor characterizing the shape and extent of the molecule in terms of its 3D co-ordinates (23). This descriptor represents a 2-dimensional projection on the $X$ - $Y$ plane of a 3 -dimensional molecule. The orientation of a molecule along the axes of inertia ( $X$-co-ordinate) casts a shadow of the molecule projected on the $X-Y$ plane. Normalized shadows are calculated by $X Y$ shadow $/ X Y$ rectangle. A positive coefficient shows that the activity increases with increase in the value of $X Y$ shadow, which means that a larger area of molecular shadow in the enclosing rectangle will benefit the activity.

The fourth descriptor, HA-dependent HDCA-1 is related to the hydrogen-acceptor(s) charged surface area of molecules (22). This descriptor is related to the hydrogen-bonding ability of the ligands and to the ability of forming polar interactions between the ligand and the receptor.

The fifth descriptor in the equation is a geometrical descriptor representing the 2 -dimensional projection on the $Z-X$ plane of a 3-dimensional molecule. A negative contribution to the linear equation indicates the decrease in activity with increase in the value of $Z X$ shadow.

Overall, this reflects that the size/volume of molecules positively govern the PPAR $\alpha$ activity, while the biological activity is influenced negatively by the hydrogen bond forming ability of thiazolidinedione and oxazolidinedione molecules. The positive contribution of size to the activity shows that hydrophobic interactions are playing a major role on the PPAR $\alpha$ activity.

The importance of the $V_{\alpha}$ descriptor (which had a low beta coefficient value but a high $t$-statistics value) in the modeling of PPAR $\alpha$

## Lather et al.

activity was observed by the development of a QSAR model without $V_{\alpha}$ (while keeping everything else unchanged relatively to the model described at the beginning of this subsection). The OSAR model without $V_{\alpha}$ resulted in an $R^{2}$ value of 0.54 with SEE of 0.68 for the training set of compounds.
$\operatorname{plC}_{50} \quad(\alpha)=-1.019 \quad( \pm 0.344) \quad$ Topograhic electronic index (all pairs) $+6.435( \pm 2.732) X Y$ shadow $-0.481( \pm 0.268)$ HA-dependent HDCA-1 - $9.649( \pm 6.534)$ ZX shadow $+15.881( \pm 4.275)$
$n=27, R^{2}=0.541, F(4,22)=6.49$, SEE $=0.683, q^{2}=0.307$
The model resulted in a low LOO cross-validation variance and $F$-test value of 6.49 (on 4 and 22 degrees of freedom). The predictability of this model was further tested on the test set molecules resulting in an $R_{\text {test }}^{2}$ value of 0.10.

## PPAR $\gamma$ model

The best MLR model for the prediction of PPAR $\gamma$ agonistic activity resulted in a 5 -parameter equation explaining up to $89 \%$ variance. The initial pool of descriptors calculated by CODESSA was reduced to a minimum of 20 in a heuristic manner followed by a forward stepwise MLR model generation in combination with $V_{\gamma}$ for PPAR $\gamma$. The best model is shown as follows:
$\mathrm{plC}_{50} \quad(\gamma)=63.312 \quad( \pm 8.397) \quad$ HASA-2/TMSA $+63.068 \quad( \pm 13.110)$ Relative No. of $N$ atoms $-0.481( \pm 0.121)$ No. of double bonds $-0.001( \pm 0.0002$ ) Gravitation index (all bonds) -0.115 $( \pm 0.0510) V_{\gamma}+8.719( \pm 0.951)$
$n=27, R^{2}=0.890, F(5,21)=33.306$, SEE $=0.195, q^{2}=0.80$
The statistical details are shown in Table 6. All the $t$-values are significant with low p -values which confirm the significance of each descriptor. The $F$-statistic (on 5 and 21 degrees of freedom) for this model was found to be 33.3 with a p-value less than 0.000 . The variance inflation factors were less than 2.5 indicating the absence of multicollinearities in the model. VIF values upto 10 are considered as statistically valid, but independent variables with values between 1 and 4 are considered as highly significant. Hence, the model is considered to be statistically valid. The predictive ability

Table 6: Statistics for the best MLR model for prediction of PPAR $\gamma$ agonistic activity

| Descriptor | beta | SE | $t$ | p level | Tolerance | VIF |
| :--- | ---: | :--- | :--- | :--- | :--- | :--- |
| Constant | 8.719 | 0.951 | 9.166 | 0.000 |  |  |
| HASA-2/TMSA | 63.312 | 8.397 | 7.540 | 0.000 | 0.405 | 2.469 |
| Relative No. <br> $n$ atoms | 63.068 | 13.110 | 4.810 | 0.000 | 0.733 | 1.364 |
| No. double <br> bonds | -0.481 | 0.121 | -3.973 | 0.000 | 0.638 | 1.567 |
| Gravitation <br> index | -0.001 | 0.0002 | -3.127 | 0.005 | 0.738 | 1.355 |
| (all bonds) | -0.115 | 0.051 | -2.260 | 0.030 | 0.456 | 2.193 |
| $V_{\gamma}$ |  |  |  |  |  |  |

of the model was validated internally by the LOO method giving a $q^{2}$ value of 0.80 , which indicates the high predictability of the model. The RMSE for the training set $\left(R^{2}=0.89\right)$ was 0.17 . The model was further validated externally by the prediction of test set compounds resulting in an $R_{\text {test }}^{2}$ value of 0.50 . Figure 3 shows a fit plot of predicted versus experimental $\mathrm{plC}_{50}$ values for the training and test set molecules.

The main descriptor for the prediction based on the $t$-statistics was found to be HASA-2/TMSA (24), a Zefirov's partial charge-based descriptor, which is equal to the square root of hydrogen bonding acceptor surface area normalized by the total molecular solvent accessible surface area, which is related to the hydrogen bonding ability of the ligands with the receptor.

The second descriptor of importance for the PPAR $\gamma$ model is the relative number of $N$ atoms and the positive coefficient indicates the increase in the activity of ligands with an increase in the relative no. of $N$ atoms, which could reflect the importance of having more polar compounds for an increased activity.

The gravitation index (all bonds) (25) is defined as

$$
\begin{equation*}
G_{b}=\sum_{i<j}^{N_{b}} \frac{m_{i} m_{j}}{r_{i j}^{2}} \tag{3}
\end{equation*}
$$

where $m_{i}$ and $m_{j}$ are the atomic masses of bonded atoms $i$ and $j$, $r_{i j}$ denotes the respective bond lengths and $N_{b}$ is the number of chemical bonds in the molecule. $G_{b}$ accounts for both the atomic masses (volumes) and for their distribution within the molecular space. It quantifies effectively the bulk cohesiveness of compounds arising from the dispersion and hydrophobic interactions. A negative coefficient for this descriptor implies that ligands with higher molecular mass have smaller PPAR $\gamma$ agonisitc activity.

The number of double bonds is a constitutional descriptor and negative coefficient in the PPAR $\gamma$ model shows that a decrease in the activity was observed with an increase in the number of double


Figure 3: Plots of predicted versus experimental PPAR $\gamma$ activities of the training and test set molecules.
bonds. It could be due to the fact that the introduction of more double bonds reduced the flexibility of the molecules and thus decrease the activity.

The last descriptor for the prediction of the PPAR $\gamma$ agonistic activity was $V_{\gamma}$, which is the volume occupied by the ligands in the binding region specific to PPAR $\gamma$. A negative coefficient value indicates that a decrease in the size or volume of ligands in this region increases the biological activity. Although the coefficient for $V_{\gamma}$ in the equation is low, it had an individual correlation coefficient of 0.65 with PPAR $\gamma$ activity for the molecules in the training set, which shows that it influences the PPAR $\gamma$ activity significantly. The negative contribution to the PPAR $\gamma$ activity can be explained on the basis that as the size of the substituents at the terminal phenyl ring increases, the biological activity decreases. As it can be observed in Figure 4, the terminal phenyl ring fits in a small hydrophilic pocket (which is specific of the PPAR $\gamma$ isoform and accounts for the $V_{\gamma}$ values), and molecules substituted with hydrophilic moieties (e.g. molecule 12 having hydroxyl substituted terminal phenyl ring) are more active. Molecules with larger and hydrophobic substituents (e.g. molecule 6 having isobutyl substituted terminal phenyl ring) make less favorable interactions with the receptor atoms and tend to be less active.

A OSAR model was also developed without $V_{\gamma}$ (while keeping everything else unchanged relatively to the model described at the beginning of this subsection) for modeling the PPAR $\gamma$ activity. The QSAR model without $V_{\gamma}$ resulted in an $R^{2}$ value of 0.86 with SEE of 0.21 for the training set of compounds.
$\mathrm{plC}_{50} \quad(\gamma)=63.312 \quad( \pm 8.397) \quad$ HASA-2/TMSA $+63.068 \quad( \pm 13.110)$ Relative No. of N atoms $-0.481( \pm 0.121) \mathrm{No}$. of double bonds $0.001( \pm 0.0002)$ Gravitation index (all bonds)

$$
n=27, R^{2}=0.860, F(5,21)=34.000, \text { SEE }=0.21, q^{2}=0.50
$$

This model resulted in a LOO cross-validation variance of $50 \%$, which was lower than that of 5 -parametric model obtained using $V_{\gamma}\left(q^{2}=0.80\right)$. Further, predictability of this model was tested on


Figure 4: Overlay of molecules 6 (Grey) and 12 (Green) docked in binding site of PPAR $\gamma$.
the test set compounds resulting in an $R_{\text {test }}^{2}$ value of 0.35 , which was also lower than that of model with $V_{\gamma}\left(R_{\text {test }}^{2}=0.50\right)$. Thus, the comparative results of the two models validate the role of $V_{\gamma}$ in the prediction of PPAR $\gamma$ activity.

## PPAR dual model

The MLR model for the prediction of PPAR dual activity resulted in a pentavariant equation explaining the $85 \%$ variance in the activity. The initial pool of descriptors calculated by CODESSA was reduced to a minimum of 21 in a heuristic manner followed by a forward stepwise MLR model generation. The product (sum of $\mathrm{plC}_{50}$ ) of the activities induced by the ligands for PPAR $\alpha$ and for PPAR $\gamma$ was used as the dependent variable. The best model is shown as:
$\mathrm{plC}_{50}$ (dual) $=-0.544( \pm 0.081)$ No. of atoms $+2.405( \pm 0.374)$ Kier \& Hall index (order 3) - $1.272( \pm 0.352$ ) No. of 0 atoms +3.858 $( \pm 1.627)$ Topographic electronic index $+80.682( \pm 51.480)$ PNSA$3 /$ TMSA $+32.390( \pm 3.508)$
$n=27, R^{2}=0.850, F(5,21)=24.08, \operatorname{SEE}=0.566, q^{2}=0.773$
The statistical details of this model are shown in Table 7. All the $t$-values are significant with low $p$-values which confirm the significance of each descriptor. The $F$-statistics (on 5 and 21 degrees of freedom) for this model was found to be 24.08 with a $p$-value lower than 0.000 . The variance inflation factors were smaller than 8.0 indicating the absence of multicollinearities in the model. Hence, the model is considered to be statistically valid. The predictive ability of the model was validated internally using the LOO method resulting in a $q^{2}$ value of 0.77 , which indicates the high predictability as well as eliminating the chance correlation of the model. The RMSE for the training set $\left(R^{2}=0.85\right)$ was 0.49 . The model was further validated externally by prediction of the test set compounds activities resulting in an $R^{2}$ value of 0.3 . However, upon removal of a single outlier (compound 25) from the test set using the $Z$-score method ( 2.5 times the SD ), the $R^{2}$ value increased to 0.69 . Figure 5 shows a fit plot of predicted versus experimental $\mathrm{plC}_{50}$ values for the training and test set molecules.

The most important descriptor based on the $t$-statistics was the number of atoms, a constitutional descriptor that describes the size of the molecule. A negative coefficient value for the descriptor

Table 7: Statistics for the best MLR model for prediction of PPARdual agonistic activity

| Descriptor | beta | SE | $t$ | p level | Tolerance | VIF |
| :--- | ---: | :--- | ---: | :--- | :--- | :--- |
| Constant | 32.390 | 3.508 | 9.232 | 0.000 |  |  |
| No. atoms | -0.544 | 0.081 | -6.715 | 0.001 | 0.131 | 7.633 |
| Kier \& Hall <br> index (order 3) | 2.405 | 0.374 | 6.427 | 0.000 | 0.322 | 3.105 |
| No. O atoms | -1.272 | 0.352 | -3.610 | 0.000 | 0.387 | 2.583 |
| Topographic <br> electronic index | 3.858 | 1.627 | 2.370 | 0.020 | 0.237 | 4.219 |
| PNSA-3/TMSA | 80.682 | 51.480 | 1.567 | 0.010 | 0.399 | 2.506 |

## Lather et al.



Figure 5: Plots of predicted versus experimental PPAR dual activities of the training and test set molecules. Outlier is shown as red circle.
indicates that an increase in the number of atoms results in a decrease of the dual activity.

The second descriptor of importance is Kier \& Hall valence connectivity index (order 3) (26). The Kier-Hall indices of molecular similarity measurements employ the Kier-Hall $\kappa$ and $\chi$ connectivity indices. The $\chi$ indices, for example, are computed according to following formula:

$$
\begin{equation*}
m x^{v}=\sum_{i=1}^{N_{s}} \prod_{k=1}^{m+1}\left(\frac{1}{\delta_{k}^{v}}\right)^{1 / 2} \tag{4}
\end{equation*}
$$

where $m$ represents the atomic valence connectivity indices, e.g. one bond path valence connectivity indices, two bond fragment valence connectivity indices, and three contiguous bond fragment valence connectivity indices, etc. $\delta_{k}^{v}$ is the valence connectivity for the kth atom in the molecular graph, which is defined as following:

$$
\delta_{k}^{v}=\frac{\left(Z_{k}^{V}-H_{k}\right)}{\left(Z_{k}-Z_{k}^{V}-1\right)}
$$

where $Z_{k}$ is the total number of electrons in the $k$ th atom, $Z_{k}^{v}$ is the number of valence electrons in the $k$ th atom, $H_{k}$ is the number of hydrogen atoms directly attached to the $k$ th non-hydrogen atom. This descriptor depicts different aspects of atom connectivity within a molecule, such as branching or flexibility. Further, this can be considered to describe the steric crowding around an atom and/or bond, which in turns impacts the accessibility of an atom/bond to interact with the receptor. Simply, this descriptor depicts the shape of the molecules and their role in binding to the target proteins.

The third descriptor represents the number of 0 atoms in the ligand molecules. A negative coefficient indicates the increase in the activity with a decrease in the number of 0 atoms.

Table 8: Proposed model for PPARdual activity based on $V_{\text {common }}$

| Model index | Nature of range in the proposed model | Index value | No. compounds falling in the range |  | Percent accuracy |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Total | Correct |  |
| $V_{\text {common }}$ | Inactive | 296.88-330.38 | 09 | 07 | 78 |
|  | Active | 332.89-363.54 | 20 | 16 | 80 |
|  | Inactive | 366.26-393.57 | 05 | 05 | 100 |

The fourth descriptor of importance is the topographic electronic index (all pairs) (22). Positive contribution of this descriptor indicates the importance of electrostatic forces for the dual activity.

The last descriptor PNSA-3/TMSA (22), which is the fractional atomic charge weighted partial negative surface area, is based on the Zefirov's partial charge calculations. PNSA-3 is calculated as:

$$
\begin{equation*}
\text { PNSA }-3=\sum_{A} q_{A} S_{A} A \in\left\{\delta_{A}<0\right\} \tag{5}
\end{equation*}
$$

where $q_{A}$ is the atomic partial charge and $S_{A}$ is the negatively charged solvent-accessible atomic surface area, and TMSA is the total molecular surface area. This descriptor is related to the induced charge asymmetry in the molecule and to the total molecular surface area. The positive contribution of this descriptor indicates the positive role of electrostatic interactions for the PPAR dual activity.

The descriptor $V_{\text {common }}$ calculated as the volume occupied by the ligands in the region common to both PPAR $\alpha$ and PPAR $\gamma$ binding sites does not appear in the final OSAR equation for the dual model. However, a model was established based on the relationship of $V_{\text {common }}$ with the PPAR dual activity. The results are shown in Table 8. Retrofit analysis of the data in Table 8 reveals the following information regarding the model based on $V_{\text {common }}$ :

- A total of 28 of 34 compounds were classified correctly in both the active and inactive ranges. The overall prediction accuracy was found to be $82.4 \%$ with respect to PPAR dual agonistic activity.
- The active range traversed between the two inactive ranges and had a $V_{\text {common }}$ value of $332.90-363.54 \AA^{3}$. Sixteen of 20 analogs in the active range were predicted correctly resulting in a success rate of prediction of $80 \%$.

The results show that an increase in the PPAR dual activity is observed as the value of $V_{\text {common }}$ increases. The occurrence of second inactive range can be explained on the basis that this descriptor depicts only the steric interactions between the ligand and receptor, and possibly other factors (see dual OSAR model at the beginning of this subsection) may also be playing a major role in the present case.

Overall, the OSAR results shows that size and hydrophobicity are the factors which play a major role in defining the PPAR $\alpha$ activity as shown by the positive contribution of $V_{\alpha}$ and $X Y$ shadow. On the other hand, PPAR $\gamma$ activity is influenced more by the H -bond forming ability of the molecules with the receptor or in other words it is more controlled by the polarity of these molecules. The PPAR dual model reflects that dual PPAR agonistic activity for the thiazolidinedione and oxazolidinedione derivatives is affected by both the size and hydrogen bond forming ability as shown by the positive influence of size and polarity parameters. This model thus appears to be a combination of PPAR $\alpha$ and PPAR $\gamma$ model and could be successfully used for the design of compounds with dual activity.

The main focus of the research work carried out in this case was the development of OSAR models which are simple, versatile, highly predictive and simultaneously taking into account the receptor information for the design of PPAR agonists. Quantitative descriptors, $V_{\text {site }}$ accounting for the volume occupied by a ligand within the common or specific regions of the binding sites, in combination with other descriptors, have been used for the development of QSAR models. The geometrical descriptors accounting for 3D information of the molecules have been computed for the same conformations as those used for the calculation of $V_{\text {site }}$ descriptors. The models developed were highly predictive as shown by the resulting statistics. This study differs from the CoMFA analysis on the same dataset carried out by Khanna et al. (9) as mentioned earlier, because it was carried out in a receptor-dependent manner. The success of a CoMFA model depends on a number of factors such as the accuracy with which one can describe the compound's bioactive conformer(s), and the ability to find superimposition rules of the bioactive conformer(s) consistent with ligand-protein interactions. Two outliers in the study by Khanna et al. were probably the outliers because of inappropriate superposition on the core molecule. This study also differs from Khanna et al. because we use different docked conformations for the development of PPAR $\alpha$ and PPAR $\gamma$ models, effectively taking receptor-dependent information under consideration in the analysis of biological activities.

Further evaluation of the OSAR models and the physical significance of the descriptors involved, lead to identify the following key features for PPAR activities of thiazolidinedione and oxazolidinedione derivatives:

- $\operatorname{PPAR} \alpha$ activity is positively influenced more by the size and shape, whereas negatively by the electrostatic interactions. This shows that hydrophobic interactions are playing major role in governing the activity. Substitution with the hydrophobic groups at R1 position will improve the PPAR $\alpha$ activity. However, the more bulky groups at R1 make the molecule inactive for PPAR $\alpha$.
- On the other hand, PPAR $\gamma$ activity is positively influenced by the electrostatic parameters rather than the size. Substituents with hydrogen-bond forming ability at R1 will be helpful in improving the PPAR $\gamma$ activity as shown by the positive contribution of HASA2/TMSA descriptor in describing the activity.
- The dual model represented the influence of size and electrostatics on the PPAR dual activity of the thiazolidinediones and oxazolidinediones. Substituents such as heteroaryl groups at R1 will improve the PPAR dual activity.


## Design of New Molecules

Based on the chemical features extracted from the developed OSAR models, new molecules were designed having selectivity for either of the PPAR isoforms and also dual activators. The docking studies of these molecules were carried out using VDock after optimization by PM3 semi-empirical method using HYPERCHEM. The numerical values for the $V_{\alpha} V_{\gamma}$ were calculated using the methodology described earlier. The chemical structures for the three designed molecules are shown in Figure 6. The predicted activities along with the calculated $V_{\text {site }}$ numerical values are given in Table 9. Analysis of these results shows clearly that the designed molecule T1 is a dual agonist, whereas T2 and T3 are more specific for the PPAR $\alpha$ and PPAR $\gamma$, respectively. Figure 7 shows the docked poses of T1 in the PPAR $\alpha$ and PPAR $\gamma$ binding sites. A PPAR dual agonist T1 having the features of PPAR dual model was designed initially by substituting the terminal phenyl ring with a heterocyclic ring substituted with a trifluoromethyl group. T2 was designed to increase the specificity for the PPAR $\alpha$ by replacing the trifluoromethyl group with a phenyl ring, as the OSAR model showed us that PPAR $\alpha$ activity is influenced mainly by size and thus hydrophobic interactions. T3 molecule has been designed with specificity for PPAR $\gamma$ by incorporating a phenylsubstituted heterocyclic ring.

## Conclusions

Structure-activity relationship studies based on the information derived from the receptor can provide a useful insight in the design of multiple activating drug molecules. Design of PPAR ligands with dual activity is one such example of targeting multiple receptors. The thiazoidinedione and oxazolidinedione derivatives used in this study are the dual-activating molecules of PPAR $\alpha$ and PPAR $\gamma$. Novel descriptors have been conceptualized which account for the volume occupied by the ligands in regions that are either common or specific to the superimposed binding sites of the targets, PPAR $\alpha$ and PPAR $\gamma$, under consideration. Statistically valid OSAR models were developed with these descriptors in combination with other geometrical, electrostatics constitutional and topological descriptors for the prediction of PPAR $\alpha$ and PPAR $\gamma$ agonistic activity. A dual PPAR model has also been developed which incorporated the structural features required for the dual PPAR activity. Correlation with these novel quantitative descriptors proves the importance of adding receptor dependent descriptors to describe the activity of ligands when designing compounds intended to target multiple receptors, and additionally they can provide an easy and intuitive way to interpret the OSAR equations facilitating the synthesis of new compounds with improved properties based on the predictions of QSAR models.

## Lather et al.



Figure 6: Chemical structures of designed molecules.

Table 9: Numerical values of $V_{\text {site }}$ descriptors and predicted activities for designed molecules

| Comp. <br> No. | $V_{\alpha}$ | $V_{\gamma}$ | $\mathrm{plC}_{50}(\alpha)$ | $\mathrm{plC}_{50}(\gamma)$ | $\mathrm{plC}_{50}$ <br> $($ dual |
| :--- | :--- | ---: | :--- | :--- | :--- |
| T1 | 30.95 | 7.68 | 7.10 | 7.70 | 15.48 |
| T2 | 35.50 | 33.14 | 6.97 | 4.35 | 13.95 |
| T3 | 28.07 | 5.14 | 8.09 | 9.54 | 18.67 |

${ }^{\text {a }}$ Predicted $\mathrm{plC}_{50}$ (dual) based on PPARdual QSAR model.


Figure 7: Docked poses of T 1 in PPAR $\alpha$ (Grey) and PPAR $\gamma$ (Orange). T1 docked pose is shown as yellow for PPAR $\alpha$ and magenta for PPAR $\gamma$.

## Acknowledgments

We thank Fundação para a Ciência e Tecnologia (Portugal) for Grant SFRH/BPD/30954/2006 attributed to Viney Lather and SFRH/BPD/20716/2004 attributed to Visvaldas Kairys.

## References

1. Baumann K. (2002) An alignment-indpendent versatile structure descriptor for QSAR and OSPR based on the distribution of molecular features. J Chem Inf Comput Sci;42:26-35.
2. Datar P.A., Coutinho E.C. (2004) A CoMFA study of COX-2 inhibitors with receptor based alignment. J Mol Graph Model;23:239-251.
3. Huang H., Pan X., Tan N., Zeng G., Ji C. (2007) 3D-QSAR study of sulfonamide inhibitors of human carbonic anhydrase II. Eur J Med Chem;42:365-372.
4. Pan D., Tseng Y., Hopfinger A.J. (2003) Quantitative structurebased design: formalism and application of receptor-dependent RD-4D-OSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J Chem Inf Model;43:1591-1607.
5. Santos-Filho O.A., Hopfinger A.J. (2006) Structure-based OSAR analysis of a set of 4 -hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: An application of the receptor-dependent (RD) 4D-OSAR formalism. J Chem Inf Model;46:345-354.
6. Graul A., Lesson P., Castaner J. (1999) Omapatrilat. Drugs Future;24:269-277.
7. Golase J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., Frost P., Ye P., Boschelli D.H., Boschelli F. (2003) SKI-606, a 4-Anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res;63:375-381.
8. Sorbera L.A., Castaner J., del Fresno M., Silvestre J. (2002) Netoglitazone. Drugs Future;27:132-139.
9. Khanna S., Sobhia M.E., Bharatam P.V. (2005) Additivity of molecular fields; CoMFA study on dual activators of PPAR $\alpha$ and PPAR $\gamma$. J Med Chem;48:3015-3025.
10. Desai R.C., Han W., Metzger E.J., Bergman J.P., Gratale D.F., MacNaul K.L., Berger J.P., Doebber T.W., Leung K., Moller D.E., Heck J.V., P S.S. (2003) 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual $\alpha / \gamma$ agonists as antidiabetic agents. Bioorg Med Chem Lett;13:2795-2798.
11. Desai R.C., Gratale D.F., Han W., Koyama H., Metzger E.J., Lombardo V.K., MacNaul K.L., Doebber T.W., Berger J.P., Leung K., Franklin R., Moller D.E., Heck J.V., P S.S. (2003) Aryloxazolidinediones: identification of potent orally active PPAR dual $\alpha / \gamma$ agonists. Bioorg Med Chem Lett;13:3541-3544.
12. Gutman I., Russic B., Trinajstic N., Wicox C.X. Jr (1975) Graph theory and molecular orbitals. XII. Acyclic polyenes. J Chem Phys;62:3399-3405.
13. Gutman I., Trinajstic N. (1972) Graph theory and molecular orbitals III. Chem Phys Lett;17:535-538.
14. Balaban A.T. (1982) Highly discriminating distance-based topological index. Chem Phys Lett;80:399-404.
15. Devillers J., Balaban A.T. (editors) (1999) Topological Indices and Related Descriptors in QSAR and QSPR. The Netherlands: Gordon and Breach.
16. Gupta S., Singh M., Madan A.K. (2001) Predicting anti-HIV activity: computational approach using novel topological descriptor. J Comput Aid Mol Des;15:671-678.
17. Nolte R.T., Wisley G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor gamma. Nature;395:137-143.
18. Kairys V., Gilson M.K. (2002) Enhanced docking with the mining minima optimizer: acceleration and side-chain flexibility. J Comput Chem;23:1656-1670.
19. Jung J., Lee B. (2000) Protein structure alignment using environmental profiles. Protein Eng;13:535-543.
20. Katritzky A.R., Oliferenko A., Lomaka A., Karelson M. (2002) Sixmembered cyclic ureas as HIV-1 protease inhibitors: A OSAR study based on CODESSA PRO approach. Bioorg Med Chem Lett;12:3453-3457.
21. Ivanciuc T., Ivanciuc 0. (2002) Quantitative structure-retention relationship study of gas chromatographic retention indices for halogenated compounds. Int Elec J Mol Des;1:94-107.
22. Katritzky A.R., Kuanar M., Fara D.C., Karelson M., Acree W.E., Solovev V.P., Varnek A. (2005) QSAR modeling of blood: air and tissue: air partition coefficients using theoretical descriptors. Bioorg Med Chem;13:6450-6463.
23. Code J.E., Perko K.E., Yourtee D.M., Holder A.J., Kostoryz E. (2007) A semi-empirical computational method for the inhibition of porcine cholesterol esterase. J Biomater Sci Polym Ed:18:1457-1474.
24. Spreafico M., Boriani E., Benfenati E., Novic M. (2007) Structural features of diverse ligands influencing binding affinities to estrogen $\alpha$ and estrogen $\beta$ receptors. Part II. Molecular descriptors calculated from conformation of the ligands in the complex resulting from previous docking study. Mol Divers;11:171-181.
25. Katritzky A.R., Dobchev D.A., Tulp I., Karelson M., Carlson D.A. (2006) OSAR study of mosquito repellents using Codessa Pro. Bioorg Med Chem Lett;16:2306-2311.
26. Kier L.B., Murray W.J., Randic M., Hall L.H. (1975) Molecular connectivity I. Relationship to nonspecific local anesthesia. J Pharm Sci;64:1971-1974.

## Notes

${ }^{\text {a }}$ The fortran source code, along with example files, needed to calculate the $V_{\text {site }}$ descriptors are available, free of charge, for download from the authors' website http://www.uma.pt/molmodel/m3l/ software.html.
${ }^{\text {b }}$ CODESSA 2.7, © 1992-2004, Shawnee, KS, USA: Semichem Inc.

